Clinical Trial Update: A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia [Phase 1]

View source ↗

Summary

A Phase 1 multiple ascending dose study of 9MW3011 in patients with beta-thalassemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• 9MW3011

Snippet

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Beta-Thalassemia | Phase 1 | Status: RECRUITING